X-Fat Global

X-Fat is a preclinical-stage biotechnology company developing innovative cell therapies to combat obesity and metabolic disorders. The company's core technology, the HUMBLE (Human Brown-Like) cell platform, utilizes CRISPR/Cas9 gene editing to convert white adipocytes into thermogenic brown-like fat cells. By transplanting these engineered cells, X-Fat aims to increase energy expenditure and improve glucose homeostasis in patients with type 2 diabetes and obesity. Founded on research from the Joslin Diabetes Center and Harvard Medical School, the company is at the forefront of brown adipose tissue-based regenerative medicine.